在一项针对不可切除的 III 期非小细胞肺癌的 I 期研究中观察到贝伐单抗与同期胸部放疗后的肺毒性。 - Suppr

Suppr

超能文献

Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer.

作者信息

Lind Joline S W, Senan Suresh, Smit Egbert F

机构信息

Vrije Universiteit University Medical Center, Amsterdam, the Netherlands.

出版信息

J Clin Oncol. 2012 Mar 10;30(8):e104-8. doi: 10.1200/JCO.2011.38.4552. Epub 2012 Feb 13.

DOI:10.1200/JCO.2011.38.4552

PMID:22331948

Abstract

摘要

相似文献

Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer.

J Clin Oncol. 2012 Mar 10;30(8):e104-8. doi: 10.1200/JCO.2011.38.4552. Epub 2012 Feb 13.

Phase I results of vinorelbine with concurrent radiotherapy in elderly patients with unresectable, locally advanced non-small-cell lung cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI).

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1777-82. doi: 10.1016/j.ijrobp.2011.03.037. Epub 2011 May 27.

Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab.

J Clin Oncol. 2010 Jan 1;28(1):43-8. doi: 10.1200/JCO.2009.24.7353. Epub 2009 Nov 9.

Osteonecrosis of the jaw in a patient with advanced non-small-cell lung cancer receiving bevacizumab.

Arch Bronconeumol. 2012 Jun;48(6):218-9. doi: 10.1016/j.arbres.2012.01.007. Epub 2012 Mar 17.

Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy.

Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):238-43. doi: 10.1016/j.ijrobp.2011.11.013. Epub 2012 Jan 31.

Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy.

J Thorac Oncol. 2014 Jun;9(6):882-5. doi: 10.1097/JTO.0000000000000126.

Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable Stage III non-small cell lung cancer using helical tomotherapy.

Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1352-9. doi: 10.1016/j.ijrobp.2009.06.075. Epub 2010 Jan 7.

A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer.

Am J Clin Oncol. 2007 Jun;30(3):239-44. doi: 10.1097/01.coc.0000256691.27796.24.

Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.

Cancer. 2005 May 15;103(10):2118-27. doi: 10.1002/cncr.21007.

Pembrolizumab-induced Radiation Recall Pneumonitis After the Resolution of Typical Asymptomatic Radiation Pneumonitis.

J UOEH. 2020;42(3):261-266. doi: 10.7888/juoeh.42.261.

引用本文的文献

Palliative Thoracic Radiotherapy in the Era of Modern Cancer Care for NSCLC.

Cancers (Basel). 2024 Aug 29;16(17):3018. doi: 10.3390/cancers16173018.

The incidence of and risk factors for radiation pneumonitis in patients treated with simultaneous bevacizumab and thoracic radiotherapy.

Radiat Oncol. 2024 May 30;19(1):67. doi: 10.1186/s13014-024-02458-x.

Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy.

J Transl Med. 2023 Jun 7;21(1):368. doi: 10.1186/s12967-023-04212-5.

Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy-A Review.

Int J Mol Sci. 2023 Mar 20;24(6):5858. doi: 10.3390/ijms24065858.

Preclinical models of radiation-induced cardiac toxicity: Potential mechanisms and biomarkers.

Front Oncol. 2022 Oct 12;12:920867. doi: 10.3389/fonc.2022.920867. eCollection 2022.

Combination of Palliative Thoracic Radiotherapy With Bevacizumab for Stage IV Nonsquamous NSCLC: Is There Any Impact of Time Interval on Survival?

Clin Med Insights Oncol. 2022 Jun 24;16:11795549221106462. doi: 10.1177/11795549221106462. eCollection 2022.

Severe Pulmonary Toxicity With Concurrent Anlotinib and Chemoradiotherapy in Stage III NSCLC: The ALTER-L042 Phase 1 Clinical Trial.

JTO Clin Res Rep. 2022 May 13;3(6):100339. doi: 10.1016/j.jtocrr.2022.100339. eCollection 2022 Jun.

Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.

Theranostics. 2022 Jan 1;12(2):747-766. doi: 10.7150/thno.65828. eCollection 2022.

Endostar (rh-endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis.

Thorac Cancer. 2021 Dec;12(23):3208-3215. doi: 10.1111/1759-7714.14188. Epub 2021 Oct 21.

Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations.

Front Oncol. 2021 Sep 29;11:752545. doi: 10.3389/fonc.2021.752545. eCollection 2021.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验